SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community celebrates recent milestones and anticipates upcoming utilities, including staking. Social media is buzzing with excitement as community members express bullish sentiment and encourage others to join the ride. The coin's active community and consistent grind are driving conversations, with many believing $BROKE.X is poised to take over alt season.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to its anticipated inclusion in the S&P 500, sparking excitement among investors who foresee institutional investment and increased visibility for the stock. The community is weighing the potential impact of the inclusion, considering historical examples and debating whether it is already priced in, while also anticipating a Robinhood summit next week.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the U.S. Department of Commerce utilizes it for on-chain economic data distribution, generating excitement about institutional adoption and the potential to disrupt the finance sector. The community is focused on potential price movements and comparing Pyth to other oracles like Chainlink. Some community members highlight Pyth's utility and government partnership as key factors for its growth.

Pineapple Financial, Inc. is a Canadian based mortgage technology and brokerage company, which engages in the mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages, and consumers. The company also provides back-office services, together with pre-underwriting support services. The company was founded by Shubha Dasgupta, Kendall Marin, and Charles Andrew Green on October 16, 2015 and is headquartered in North York, Canada.

Pineapple Financial Inc

Pineapple Financial ($PAPL) is trending after a large private placement and a move into Injective (INJ) crypto, sparking excitement about its digital asset strategy. The community is actively discussing potential short squeezes and high price targets, while some caution about possible dilution. With a small float and high borrow costs, the stock's volatility is attracting both bulls and bears.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

Gyrodyne ($GYRO) is trending amid discussions of its low float and potential for a significant breakout, with some traders drawing comparisons to previous high-momentum stocks. The community is closely watching key breakout levels, anticipating a rapid price surge if certain thresholds are breached. Some traders also highlight the company's real estate assets, suggesting they could drive further gains.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending due to discussions around a reported link between Tylenol use during pregnancy and autism, spurred by comments from RFK Jr., creating a sharp sell-off. While some community members see this as a buying opportunity, citing the wide use of Tylenol and disputing the claims, others are concerned about potential lawsuits and negative perception impacting the stock. The broader discussion includes potential market manipulation and comparisons to other companies facing similar headline risks.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending amid discussions about its recent performance and future prospects, with community members debating its potential in light of upcoming data releases and expressing varied opinions on its valuation. Bullish investors are focused on the company's pipeline and potential partnerships, while bears express concerns about cash runway and dilution. Recent job postings and institutional interest are also fueling some positive sentiment.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending as the community discusses recent price manipulation, potential shakeouts, and a large insider buy, fueling speculation of a breakout. Bullish investors are focused on upcoming conferences and pipeline updates, particularly around CTX112, while noting that ARK Invest continues to accumulate shares. Some traders express frustration with intraday volatility, attributing it to market maker tactics and short squeezes.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as investors discuss the impact of a recent reverse stock split and its potential effects on the stock's price. While some express optimism about the company's technology and long-term prospects, others are concerned about dilution and the company's financials, leading to a debate about its future amid NFL commercial exposure.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is trending as community members discuss its potential for significant growth and utility, particularly as a faster, cheaper alternative to Bitcoin. Conversations also revolve around potential price targets and whether BCH can outperform Bitcoin as market focus shifts. Some traders are watching for a breakout, while others point to its tokenomics and the possibility of a spot ETF.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Turnstone Biologics Corp. (TSBX) jumped over 5% on Friday morning after the company said that it has entered into a definitive merger agreement whereby XOMA Royalty Corporation (XOMA) will acquire Turnstone.As per the <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.xoma.com/news-events/press-releases/detail/477/turnstone-biologics-corp-enters-into-agreement-to-be">agreement</a>, XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock plus one non-transferable contingent value right.The upfront payment of $0.34 represents a 2.4% upside to the stock’s closing price on Thursday.<a href="https://stocktwits.com/symbol/TSBX">Turnstone Biologics</a> is a biotechnology company developing new medicines to treat and cure patients with solid tumors. Its Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best interests of all Turnstone stockholders and has approved the merger agreement and related transactions, the company said. &nbsp;The merger transaction is expected to close in August 2025.<a href="https://stocktwits.com/symbol/XOMA">XOMA Royalty</a>, meanwhile, is a biotechnology royalty aggregator – &nbsp;a company that acquires the rights to future royalties and milestone payments from biopharmaceutical companies – with over 120 assets. Royalty aggregators typically provide a form of non-dilutive financing for biotech companies, allowing them to access capital without selling equity or taking on debt.Turnstone had cash, cash equivalents, and short-term investments of only $21.9 million as of the end of the first quarter (Q1). The company’s net loss in the three months through the end of March this year was $11.8 million, compared to a net loss of $19.6 million for the same period in 2024.On Stocktwits, retail sentiment around XOMA jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours while sentiment around TSBX slumped from ‘neutral’ to ‘bearish’.<figure class="image"><img style="aspect-ratio:1258/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_27_at_11_05_04_AM_png_dd0f3102eb.webp" alt="XOMA's Sentiment Meter and Message Volume as of 11:05 a.m. ET on June 27, 2025 | Source: Stocktwits" width="1258" height="128"><figcaption>XOMA's Sentiment Meter and Message Volume as of 11:05 a.m. ET on June 27, 2025 | Source: Stocktwits</figcaption></figure><figure class="image"><img style="aspect-ratio:1252/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_27_at_11_05_23_AM_png_688b06d81a.webp" alt="TSBX's Sentiment Meter and Message Volume as of 11:05 a.m. ET on June 27, 2025 | Source: Stocktwits" width="1252" height="128"><figcaption>TSBX's Sentiment Meter and Message Volume as of 11:05 a.m. ET on June 27, 2025 | Source: Stocktwits</figcaption></figure>While XOMA is up by 5% this year, TSBX is down by about 30%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-ropes-in-former-exec-of-gm-cruise-as-head-of-autonomy/chmgyoCRRIU">Tesla Ropes In Former Exec Of GM’s Failed Self-Driving Unit As Head Of Autonomy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps

XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock plus one non-transferable contingent value right.

Equity

Piper Sandler Remains a Buy on Turnstone Biologics Corp. (TSBX)

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Turnstone Biologics Corp. (TSBX Research Report), with...

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors...

Turnstone Biologics to Participate in Upcoming Investor Conferences

SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ( Turnstone or the Company ) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to...

Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ( Turnstone or the Company ) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to...

Turnstone Biologics Corp. operates as a clinical stage biotechnology company. It engages in the business of developing and commercializing therapeutics. The company is focused on developing new medicines to treat and cure patients with solid tumors. Turnstone Biologics was founded in 2015 and is headquartered in La Jolla, CA.

TSBX
Turnstone Biologics Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TSBX News

TSBX Turnstone Biologics Corp